【摘要】 目的观察重组基因干扰素α-1b与胸腺肽治疗慢性乙型病毒性肝炎(CHB)的临床疗效。方法选择门诊及住院的慢性乙型病毒性肝炎患者140例,其中干扰素治疗组90例;保肝治疗组60例。观察2组患者的肝功能。结果干扰素联合胸腺肽治疗组的ALT复常率和HbeAg阴转率均明显高于保肝治疗组,差异均有统计学意义(P<0.01)。结论干扰素α-1b与胸腺肽是目前治疗慢性乙型病毒性肝炎较为有效的药物。更多还原

【Abstract】 Objective To observe the clinical impact factors and safety of recombinant human in terferon α-Ib and thymic peptide for treatmemt of chronic hepatitis B(CHB)cases.Methods Total 150 CHB cases selected from out-and in-patients were divided into 2 groups:90 cases in α-lb and thymic peptide treatment group,and 60 cases in liver protective group.ALT level and number of copies of HBV-DNA was detected.Results In α-lb and tkymic peptide treatment group,the HbeAg negative rate,HbeAg serum inversion rate and HBV DNA negative rate were significantly higher than that in liver protective group(P<0.01).Conclusion α-lb interferon and thymic peptide is one of the effective and safe medicines for treating CHB.更多还原